Clinical Trials

1,096 enrolled 17 charts 1 FDA

Carcinoma, Renal Cell

NCT02568267 2026-05-27

STARTRK-2

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

534 enrolled 1 FDA

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

6,452 enrolled 1 FDA

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04195750 2026-05-14

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

755 enrolled 28 charts 1 FDA

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01946204 2026-05-11

SPARTAN

1,207 enrolled 15 charts 1 FDA

Prostatic Neoplasms

NCT02489318 2026-05-11

TITAN

1,052 enrolled 13 charts 1 FDA

Prostatic Neoplasms

NCT04497844 2026-05-11

AMPLITUDE

696 enrolled 15 charts 1 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT05243550 2026-05-11

ENVISION

240 enrolled 20 charts 1 FDA

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02365597 2026-05-08

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

239 enrolled 32 charts 1 FDA

Urothelial Cancer

NCT03748641 2026-05-08

MAGNITUDE

765 enrolled 16 charts 1 FDA

Prostatic Neoplasms, Castration-Resistant

NCT04640623 2026-05-08

SunRISe-1

220 enrolled 1 FDA

Urinary Bladder Neoplasms

NCT02319837 2026-05-07

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

1,068 enrolled 20 charts 1 FDA

Prostatic Neoplasms

NCT04660344 2026-03-27

IMvigor011

761 enrolled 1 FDA

Phase 1/2 Active not recruiting

Muscle-invasive Bladder Cancer

NCT02650401 2026-03-25

STARTRK-NG

69 enrolled 1 FDA

CNSEndocrineGenitourinaryHead & NeckSarcoma

Thyroid Cancer, Papillary, Brain Neoplasms, Glioma, Medulloblastoma, Neoplasm Metastasis, Wilms Tumor, Neuroblastoma, Recurrence, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Ewing, Central Nervous System Neoplasms, Nephroma, Mesoblastic

NCT03288545 2026-03-24

EV-103

Phase 1/2 Terminated

348 enrolled 1 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT04689828 2026-03-23

PSMAfore

469 enrolled 11 charts 1 FDA

Prostatic Neoplasms

NCT03547973 2026-03-16

TROPHY U-01

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer

NCT03732677 2026-03-13

NIAGARA

1,063 enrolled 15 charts 1 FDA

Urinary Bladder Neoplasms

NCT03142334 2026-03-10

KEYNOTE-564

994 enrolled 10 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT03036098 2026-03-06

CheckMate901

1,314 enrolled 23 charts 1 FDA

Urothelial Cancer

NCT02811861 2026-02-23

CLEAR

1,069 enrolled 12 charts 1 FDA

Carcinoma, Renal Cell

NCT02853331 2026-02-02

KEYNOTE-426

861 enrolled 24 charts 1 FDA

Carcinoma, Renal Cell

NCT03732820 2026-01-29

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

895 enrolled 19 charts 1 FDA

Metastatic Castration-resistant Prostate Cancer

NCT02003924 2026-01-27

PROSPER

1,401 enrolled 25 charts 1 FDA

Prostatic Neoplasms

NCT03474107 2026-01-09

A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

608 enrolled 22 charts 1 FDA

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT02799602 2025-12-04

ARASENS

1,306 enrolled 25 charts 2 FDA

Metastatic Hormone-sensitive Prostate Cancer

NCT02677896 2025-10-24

ARCHES

1,150 enrolled 23 charts 1 FDA

Phase 2/3 Active not recruiting

Metastatic Hormone Sensitive Prostate Cancer

NCT03022825 2025-10-16

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

190 enrolled 1 FDA

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04810078 2025-10-09

CheckMate-67T

681 enrolled 1 FDA

Carcinoma, Renal Cell

NCT03924895 2025-08-28

KEYNOTE-905

595 enrolled 1 FDA

Urinary Bladder Neoplasms

NCT02684006 2025-07-30

JAVELIN Renal 101

886 enrolled 37 charts 1 FDA

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

NCT02975934 2025-07-25

TRITON3

405 enrolled 34 charts 1 FDA

Metastatic Castration Resistant Prostate Cancer

NCT04223856 2025-06-13

EV-302

886 enrolled 12 charts 1 FDA

Urothelial Cancer

NCT03141177 2025-06-06

CheckMate 9ER

701 enrolled 17 charts 1 FDA

Carcinoma, Renal Cell

NCT01715285 2025-02-04

A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)

1,209 enrolled 16 charts 1 FDA

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT03212404 2025-02-03

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

272 enrolled 1 FDA

DermatologicGenitourinaryGynecologicHead & NeckLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasms, Skin Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Carcinoma, Small Cell

NCT03511664 2025-01-13

VISION

861 enrolled 39 charts 1 FDA

219 enrolled 32 charts 2 FDA

Prostatic Neoplasms

NCT03219333 2024-08-27

EV-201

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT02773849 2024-07-29

ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

157 enrolled 22 charts 1 FDA

Non-Muscle Invasive Bladder Neoplasms

NCT02603432 2024-03-27

JAVELIN Bladder 100

700 enrolled 35 charts 1 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT00716976 2023-11-09

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

131 enrolled 18 charts 1 FDA

CNSGastrointestinalGenitourinaryGynecologicSarcoma

Ovarian Germ Cell Cancer, Ototoxicity, Brain Neoplasms, Liver Neoplasms, Medulloblastoma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Teratoma, Testicular Neoplasms, Central Nervous System Neoplasms, Hepatoblastoma

NCT02987543 2023-10-06

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

387 enrolled 16 charts 1 FDA

Metastatic Castration-resistant Prostate Cancer

NCT02627963 2023-07-18

A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)

350 enrolled 14 charts 1 FDA

Carcinoma, Renal Cell

NCT02200614 2022-06-28

ARAMIS

1,509 enrolled 13 charts 1 FDA

Prostate Cancer Non-Metastatic

NCT03085095 2022-01-18

HERO

1,134 enrolled 38 charts 1 FDA

515 enrolled 28 charts 1 FDA

Prostatic Neoplasms

NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Phase 1/2 Completed

BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01835158 2021-02-11

Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

Phase 2 Completed

157 enrolled 10 charts 1 FDA

Carcinoma, Renal Cell

NCT02793128 2020-12-22

Olympus

71 enrolled 16 charts 1 FDA